- Home
- IMCR vs BCAT Comparison
IMCR vs BCAT Comparison
Compare IMCR & BCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- BCAT
- Stock Information
- Founded
- IMCR 2008
- BCAT 2020
- Country
- IMCR United Kingdom
- BCAT United States
- Employees
- IMCR N/A
- BCAT N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- BCAT Finance/Investors Services
- Sector
- IMCR Health Care
- BCAT Finance
- Exchange
- IMCR Nasdaq
- BCAT Nasdaq
- Market Cap
- IMCR 1.5B
- BCAT 1.5B
- IPO Year
- IMCR 2021
- BCAT N/A
- Fundamental
- Price
- IMCR $32.77
- BCAT $15.26
- Analyst Decision
- IMCR Buy
- BCAT
- Analyst Count
- IMCR 10
- BCAT 0
- Target Price
- IMCR $58.13
- BCAT N/A
- AVG Volume (30 Days)
- IMCR 445.1K
- BCAT 308.8K
- Earning Date
- IMCR 08-07-2025
- BCAT 01-01-0001
- Dividend Yield
- IMCR N/A
- BCAT 9.38%
- EPS Growth
- IMCR N/A
- BCAT N/A
- EPS
- IMCR N/A
- BCAT 1.43
- Revenue
- IMCR $333,581,000.00
- BCAT N/A
- Revenue This Year
- IMCR $26.82
- BCAT N/A
- Revenue Next Year
- IMCR $8.15
- BCAT N/A
- P/E Ratio
- IMCR N/A
- BCAT $11.41
- Revenue Growth
- IMCR 25.75
- BCAT N/A
- 52 Week Low
- IMCR $23.15
- BCAT $13.67
- 52 Week High
- IMCR $41.54
- BCAT $16.38
- Technical
- Relative Strength Index (RSI)
- IMCR 45.73
- BCAT 60.91
- Support Level
- IMCR $30.76
- BCAT $14.93
- Resistance Level
- IMCR $32.55
- BCAT $15.26
- Average True Range (ATR)
- IMCR 1.39
- BCAT 0.14
- MACD
- IMCR -0.41
- BCAT 0.01
- Stochastic Oscillator
- IMCR 19.09
- BCAT 84.21
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.